

## **Acknowledgements**

I would like to mention all those to whom I am so indebted for their help and support during my research work. I am deeply grateful to Prof. John Walker for not only accepting me as a Ph.D. student in the first place, but also for providing the solution to many seemingly intractable problems I encountered along the way. I am especially thankful to Dr C J Whelan (principle supervisor), without whose constant help and encouragement, none of my work would have been possible. Another great support and source of inspiration has been my co-supervisor, Prof. M E Parsons.

My study is a continuation of the work began by Deri Morgan, who helped me enormously in the early stages of my work. No research student can work for long without the ever-ready assistance from the technical staff and I have been extremely fortunate in this regard to be the recipient of so much help and encouragement from Brian Brandford and Diana Francis in particular amongst others in the technical staff. I have enjoyed working with my fellow Ph.D colleagues, Andrea Summers and Ken Ihenetu.

Lastly, I would like to thank my husband Mark Smith and his parents, Billy and Pam, for their constant support and help throughout, especially in the latter stages with the writing.

## Abstract

Nicotine exerts a therapeutic effect in ulcerative colitis (UC) but the mechanism underlying this effect, is not clear. However, this effect may imply that nicotine has some, as yet to be discovered, effect on the immune system. The aim of the work described in this thesis was to characterise the nicotinic acetylcholine receptors (nAChRs) on human peripheral blood lymphocytes in term of receptor subtype. To achieve this, a combination of radioligand binding assays, pharmacological and molecular biological techniques were used.

The data obtained from the binding studies suggested that the presence of one binding site for (-)- nicotine on human peripheral blood lymphocytes with a  $K_d$   $15 \pm 5.759$  nM ( $1.5 \pm 5.759 \times 10^{-8}$  M) and  $B_{max}$   $2253 \pm 409$  sites/cell. The competition studies showed that ligands competing with [ $^3$ H]-(-)-nicotine were (-)-nicotine, epibatidine and  $\alpha$ -bungarotoxin, while others ligands for nAChRs displaced radiolabelled nicotine in insignificant quantities. Thus, radioligand-binding experiments suggest that the binding site for nicotine on human peripheral blood lymphocytes is a nAChR containing  $\alpha 7$  and possibly  $\alpha 4$  or/and  $\beta 2$  containing nAChR subunits. No evidence was obtained to suggest the presence of a non-cholinergic nicotine receptor. Furthermore, considerable subject to subject variation in the specific binding of radiolabelled nicotine was observed. Because of this only tentative conclusions could be drawn from radioligand binding data.

Polymerase chain reaction (RT-PCR) was then used to demonstrate mRNA for the subunits of nAChRs suggested by radioligand binding studies. Data obtained show that the human peripheral blood lymphocytes tested, expressed mRNAs for  $\alpha 4$ ,  $\alpha 5$ ,  $\alpha 7$ ,  $\beta 2$  neuronal nAChRs subunits and  $\beta 1$  muscle nAChR subunit.

Expression of the  $\alpha 5$  mRNA subunit of nAChR was observed in the lymphocytes in each sample of lymphocytes tested. In contrast, the expression pattern of mRNAs for  $\alpha 4$ ,  $\alpha 7$ ,  $\beta 1$ , and  $\beta 2$  mRNAs subunits of nAChRs, varied between individuals.

Finally, Western blot analysis was used to confirm that mRNA expression resulted in the expression of protein for nAChR subunits in human peripheral lymphocytes using monoclonal antibodies against  $\alpha 4$ ,  $\alpha 5$ ,  $\alpha 7$ , and  $\beta 2$  nAChR subunits, which had been detected by RT-PCR.

The results obtained from the Western blot analysis show that protein for  $\alpha 4$ ,  $\alpha 5$ , and  $\alpha 7$  nAChR subunits was expressed in most, but not all of the human peripheral blood lymphocyte samples tested and some of the bands obtained were faint. In contrast, protein for the  $\beta 2$  nAChR subunit was observed in a few samples tested and the bands were faint.

From the results obtained in this study, it is possible to conclude that human peripheral blood lymphocytes may contain nAChRs with subunit compositions of  $\alpha 4\beta 2$ ,  $\alpha 4\beta 2\alpha 5$ , and/or  $\alpha 7$ . However, further studies are necessary to show whether or not the single binding site for nicotine demonstrated by radioligand binding experiments is due to one or all of these nAChRs.

Thus, the findings of the present study suggest the presence of nAChR on human peripheral blood lymphocytes. Nicotine and its effect may occur through these non-neuronal nAChRs mechanisms. Such a mechanism of action could account for the beneficial of nicotine in ulcerative colitis. Furthermore, a compound that acts on these receptors, but not on nAChRs found on other cells may have therapeutic utility in the treatment of inflammation.

# CONTENTS

ACKNOWLEDEMENTS.....	I
ABSTRACT.....	II
CONTENTS.....	V
LIST OF FIGURES.....	IX
LIST OF TABLES.....	XVIII
ABBREVIATIONS.....	XIX
LIST OF CHEMICALS AND REAGENTS.....	XXII
CHAPTER 1: INTRODUCTION.....	1
1.0 The nicotinic acetylcholine receptor.....	1
1.1 Structure of nicotinic acetylcholine receptors .....	4
1.2 The Transmembrane structure of nAChR subunit.....	9
1.3 The ligand binding sites.....	12
1.3.1 Acetylcholine (Ach) binding site.....	13
1.3.2 Allosteric binding sites.....	16
1.3.3 Receptors desensitisation by phosphorylation.....	18
1.4 Transition states of nAChRs.....	18
1.5 The pharmacological diversity of nicotinic acetylcholine receptors.....	21
1.6 Evidence for non-neuronal cholinergic nicotine receptors.....	29
1.7 Evidence of nAChRs in lymphocytes and immune cells.....	32
1.8 Pharmacology and pharmacokinetics of nicotine.....	41
1.9 Effects of nicotine on nAChRs.....	44
1.10 The effect of nicotine on the immune/inflammatory system.....	46
1.11 Aims of thesis.....	51
CHAPTER 2: NICOTINE RECEPTOR BINDING STUDIES.....	53

<b>2.1 Introduction.....</b>	<b>53</b>
<b>2.2 Materials and methods.....</b>	<b>56</b>
<b>2.2.1 Materials.....</b>	<b>56</b>
<b>2.2.2 Methods.....</b>	<b>60</b>
<b>2.2.2.1 Isolation of human lymphocytes.....</b>	<b>60</b>
<b>2.2.2.2 Leukocyte counting and viability checking.....</b>	<b>63</b>
2.2.2.2.1 Leukocyte counting.....	63
2.2.2.2.2 Cell viability checking by Trypan blue dye exclusion method.....	65
<b>2.2.2.3 Cytospin slide preparation.....</b>	<b>65</b>
<b>2.2.2.4 Slide staining (May Grunwald-Geimsa stain).....</b>	<b>66</b>
<b>2.2.2.5 Radioligand binding studies.....</b>	<b>66</b>
[ <sup>3</sup> H]-(-)-Nicotine binding studies.....	66
Kinetic studies.....	68
Saturation studies.....	68
Competitive studies.....	69
2.2.2.2.5.1 Data analysis.....	70
<b>2.3 Results.....</b>	<b>71</b>
<b>2.3.1 Characterisation of human lymphocytes.....</b>	<b>71</b>
Yield of lymphocytes.....	71
2.3.1.1 Viability of cellular preparation.....	72
<b>2.3.2 Radioligand binding experiments.....</b>	<b>74</b>
2.3.2.1 Kinetic binding experiments.....	74
2.3.2.2 Saturation binding experiments.....	79
2.3.2.3 Competition binding studies.....	81

<b>2.4 Discussion.....</b>	<b>91</b>
<b>CHAPTER 3: DETERMINING THE PRESENCE OF mRNA FOR</b>	
<b>THE SUBUNIT OF nAChR IN HUMAN PERIPHERAL BLOOD</b>	
<b>LYMPHOCYTES.....</b>	<b>104</b>
<b>3.1 Introduction.....</b>	<b>104</b>
<b>3.2 Materials and methods.....</b>	<b>107</b>
<b>3.2.1 DEPC (diethyl pyrocarbonate) treatment.....</b>	<b>107</b>
<b>3.2.2 RNA Isolation from human peripheral</b>	
<b>blood lymphocytes.....</b>	<b>107</b>
3.2.2.1 Quantification and determination of quality of total RNA.....	110
<b>3.2.3 Design of the nAChR primers for RT-PCR.....</b>	<b>112</b>
<b>3.2.4 Reverse transcriptase polymerase chain reaction (RT-PCR).....</b>	<b>115</b>
3.2.4.1 RT-PCR reaction mixture and PCR cycling protocol.....	116
<b>3.2.5 Analysis of PCR products by gel electrophoresis.....</b>	<b>117</b>
<b>3.3 Results.....</b>	<b>119</b>
<b>3.3.1 Yield and purity of total RNA.....</b>	<b>119</b>
<b>3.3.2 RT-PCR.....</b>	<b>124</b>
<b>3.4 Discussion.....</b>	<b>131</b>
<b>CHAPTER 4: DETERMINATION OF nAChR SUBUNIT PROTEIN IN HUMAN</b>	
<b>PERIPHERAL BLOOD LYMPHOCYTE MEMBRANES BY</b>	
<b>IMMUNOBLOTTING.....</b>	
	<b>138</b>
<b>4.1 Introduction.....</b>	<b>138</b>
<b>4.2 Materials and Methods.....</b>	<b>141</b>
<b>4.2.1 Materials.....</b>	<b>141</b>
<b>4.2.2 Methods.....</b>	<b>143</b>

<b>4.2.2.1 Preparation of protein from human</b>	
peripheral blood lymphocytes.....	143
<b>4.2.2.2 Preparation of membrane protein from rat brain.....</b>	<b>144</b>
<b>4.2.2.3 Protein assay.....</b>	<b>145</b>
<b>4.2.2.4 Western blotting.....</b>	<b>146</b>
4.2.2.4.1 Sodium dodecyl sulphate polyacrylamide gel (SDS-	
PAGE) preparation.....	146
4.2.2.4.2 Gel electrophoresis.....	151
4.2.2.4.3 Protein staining with Coomassie blue.....	151
4.2.2.4.4 Transfer of proteins to nitrocellulose membranes.....	152
4.2.2.4.5 Immunoblotting.....	154
4.2.2.4.6 Detection protocol for Enhanced Chemiluminescence	
(ECL).....	155
<b>4.3 Results.....</b>	<b>156</b>
<b>4.4 Discussion.....</b>	<b>169</b>
<b>CHAPTER 5: GENERAL DISSCUSSION.....</b>	<b>177</b>
<b>CHAPTER 6: FUTURE WORK.....</b>	<b>192</b>
<b>REFFERENCES.....</b>	<b>196</b>
<b>APPENDIX I.....</b>	<b>256</b>
<b>APPENDIX II.....</b>	<b>261</b>

## **LIST OF FIGURES**

<b>Figure 1.1</b> The muscle type nAChR channel comprises of five subunits, of which two $\alpha$ subunits are separated by the $\gamma$ subunit. When two molecules of ACh bind to $\alpha$ subunits on the membrane surface, the receptor channel changes shape. A pore opens in that part of channel, which is embedded in the lipid bilayer and cations (e.g. $K^+$ , $Na^+$ ) flow through the opening channel.....	6
<b>Figure 1.2</b> A pentameric structure of nAChR, subunit stoichiometry and a number of binding sites of muscle type, neuronal heteromeric $\alpha 4\beta 2$ , and $\alpha 3\beta 2\beta 4\alpha 5$ types and homomeric $\alpha 7$ , $\alpha 8$ , and $\alpha 9$ nAChRs.....	7
<b>Figure 1.3</b> The nAChR sequence showing the hydrophilic extracellular domain containing the Ach binding site, four transmembrane segments M1-M4, the intracellular hydrophobic domain and the small C terminal domain. The hydrophilic domain separating M3 from M4 faces the cytoplasm. It contains functional phosphorylation sites.....	10
<b>Figure 1.4A</b> Functional model of nAChR.....	11
<b>Figure 1.4B</b> Model of the structure of channel gating.....	12
<b>Figure 1.5A</b> Subunit arrangement of muscle type nAChRs (left), and homomeric $\alpha 7$ and heteromeric of neuronal type nAChRs with 2 or 5 subunits (middle and right). The agonist binding sites are indicated by black shaded pockets, which contributed by loops A, B and C of the “principal component” and loops D, E, and F of the “complementary component”.....	15
<b>Figure 1.5B</b> Ligand binding sites of nAChR. The principal component that consists of three loops A, B, and C on the $\alpha$ subunit; the complementary component, consisting of loops D, E, and F which are present on the $\gamma$ or $\delta$ subunits of muscle type receptor -	

an $\alpha$ subunits of homopentameric or $\beta$ subunits of heteromeric neuronal nAChRs.....	16
<b>Figure 1.6</b> Cross section of nAChR. The ion channel, Ach binding site and multiple allosteric sites are located throughout the N- terminal extracellular domain. These allosteric sites include the non-competitive allosteric activator site (NCA); non-competitive sites (NCB); binding sites for $\text{Ca}^{+2}$ and steroids and phosphorylation (P) sites.....	17
<b>Figure 1.7</b> Simplified scheme of converting states of nAChRs.....	18
<b>Figure 1.8</b> Major pathways of nicotine metabolism.....	43
<b>Figure 2.1</b> Structures of ligands used for competition studies.....	59
<b>Figure 2.2</b> A diagrammatic representation of isolation of human lymphocytes using HISTOPAQUE®-1077 (MNs= Mononuclear cells, PMNs = Polymorphonuclear cells).....	62
<b>Figure 2.3</b> A diagram showing how to count cells using a haematocytometer.....	64
<b>Figure 2.4</b> A photograph of a typical cytopsin preparation of purified human peripheral blood lymphocytes used in the present study.....	73
<b>Figure 2.5</b> Time course for equilibration of [ $^3\text{H}$ ]-(-)-nicotine with human lymphocytes. Each point represents the mean $\pm$ SEM of data from 4 donors performed in triplicate. The non-specific binding was determined by the use of $10^{-5}\text{M}$ cold unlabeled-(-)-nicotine. Specific binding is the difference between total and non-specific binding. [ $^3\text{H}$ ]-(-)-Nicotine $2 \times 10^{-8}\text{M}$ (20nM) bound to human lymphocytes in a time-specific manner. From these data half time values of association were calculated by Prism software.....	75
<b>Figure 2.6.</b> Time course for equilibration of binding of [ $^3\text{H}$ ]-(-)-nicotine ( $2 \times 10^{-8}\text{M}$ or 20 nM) to intact human lymphocytes at $4^\circ\text{C}$ . Specific binding data were analysed by	

Prism and the half-life of association was obtained. The half-time for association ( $T_{1/2}$ ) was  $12.02 \pm 5.15$  minutes. Each point represents the mean  $\pm$  SEM of data from 4 donors.....76

**Figure 2.7** A dissociation time course for binding of [ $^3\text{H}$ ]-(-)-nicotine ( $2 \times 10^{-8}\text{M}$  or 20nM) to human lymphocytes. Dissociation was determined by the reduction of nicotine bound at different time points after addition of an excess of cold unlabeled(-)-nicotine ( $1 \times 10^{-5}\text{M}$ ). Data shown are from a representative experiment performed in triplicate from 4 different donors.  $T_{1/2}$  was  $20.61 \pm 6.96$  minutes.....78

**Figure 2.8** Saturation binding of [ $^3\text{H}$ ]-(-)-nicotine to human lymphocytes. The graph shows specific binding of [ $^3\text{H}$ ]-(-)-nicotine to human lymphocytes. The results were obtained from a filtration assay conducted at 4 °C for 50 minutes. Data represented are the mean  $\pm$  SEM of 5 experiments and each experiment was performed in triplicate. The  $B_{max}$  of binding site was  $2253 \pm 409.00$  sites/cells and  $K_d$  was  $15.00 \pm 5.759$  nM ( $1.5 \pm 5.759 \times 10^{-8}\text{M}$ ).....80

**Figure 2.9** Competition binding of [ $^3\text{H}$ ]-(-)-nicotine to human lymphocytes by unlabeled(-)-Nicotine. Cells were incubated with 15 nM ( $1.5 \times 10^{-8}\text{M}$ ) [ $^3\text{H}$ ]-(-)-nicotine in the presence of a serial dilution of (-)-nicotine for 35 minutes, at 4°C. This is a single experiment in graphical form for nicotine. Each point is the mean of a single concentration performed in triplicate.  $\text{IC}_{50}$  values were calculated from 5 replicate experiments and the mean S.E.M calculated.  $\text{Log} \{[\text{drug}], \text{M}\} = \text{Log drug concentration (M)}$ .....82

**Figure 2.10** Competition binding of [ $^3\text{H}$ ]-(-)-nicotine to human lymphocytes by hexamethonium. Cells were incubated with 15 nM [ $^3\text{H}$ ]-(-)-nicotine in the presence of a serial dilution of hexamethonium for 35 minutes at 4°C. This is a single experiment in graphical form for hexamethonium. Each point is the mean of a single concentration

performed in triplicate. IC50 values were calculated from 5 replicate experiments and the mean S.E.M calculated.  $\text{Log} \{[\text{drug}], \text{M}\} = \text{Log drug concentration (M)}$ .....83

**Figure 2.11** Competition binding of [<sup>3</sup>H]-(-)-nicotine to human lymphocytes by carbachol. Cells were incubated with 15 nM [<sup>3</sup>H]-(-)-nicotine in the presence of a serial dilution of carbachol for 35 minutes at 4°C. This is a single experiment in graphical form for carbachol. Each point is the mean of a single concentration performed in triplicate. IC50 values were calculated from 5 replicate experiments and the mean S.E.M calculated.  $\text{Log} \{[\text{drug}], \text{M}\} = \text{Log drug concentration (M)}$ . .....84

**Figure 2.12** Competition binding of [<sup>3</sup>H]-(-)-nicotine to human lymphocytes by cytisine. Cells were incubated with 15 nM [<sup>3</sup>H]-(-)-nicotine in the presence of a serial dilution of cytisine for 35 minutes at 4°C. This is a single experiment in graphical form for cytisine. Each point is the mean of a single concentration performed in triplicate. IC50 values were calculated from 5 replicate experiments and the mean and S.E.M calculated.  $\text{Log} \{[\text{drug}], \text{M}\} = \text{Log drug concentration (M)}$ .....85

**Figure 2.13** Competition binding of [<sup>3</sup>H]-(-)-nicotine to human lymphocytes by epibatidine. Cells were incubated with 15 nM [<sup>3</sup>H]-(-)-nicotine in the presence of a serial dilution of epibatidine for 35 minutes at 4°C. This is a single experiment in graphical form for epibatidine. Each point is the mean of a single concentration performed in triplicate. IC50 values were calculated from 5 replicate experiments and the mean and S.E.M calculated.  $\text{Log} \{[\text{drug}], \text{M}\} = \text{Log drug concentration (M)}$ .....86

**Figure 2.14** Competition binding of [<sup>3</sup>H]-(-)-nicotine to human lymphocytes by  $\alpha$  bungarotoxin. Cells were incubated with 15 nM [<sup>3</sup>H]-(-)-nicotine in the presence of a serial dilution of alpha bungarotoxin for 35 minutes at 4°C. This is a single experiment in graphical form for  $\alpha$  bungarotoxin. Each point is the mean of a single concentration

performed in triplicate. IC50 values were calculated from 5 replicate experiments and the mean and S.E.M calculated.  $\text{Log}\{[\text{drug}], \text{M}\} = \text{Log drug concentration (M)}$ .....87

**Figure 2.15** Competition binding of [<sup>3</sup>H]-(-)-nicotine to human lymphocytes by atropine. Cells were incubated with 15 nM [<sup>3</sup>H]-(-)-nicotine in the presence of a serial dilution of atropine for 20 minutes. This is a single experiment in graphical form for atropine. IC50 values were calculated from 5 replicate experiments and the mean and S.E.M calculated. Each point is the mean of a single concentration performed in triplicate.  $\text{Log}\{[\text{drug}], \text{M}\} = \text{Log drug concentration (M)}$ .....88

**Figure 3.1** Figure 3.1 A photograph of total RNA isolated from human peripheral blood lymphocytes using RNA-STAT 60™ reagent and visualised by ethidium bromide staining on a 1.0 % agarose gel electrophoresis. Lane M = DNA Ladder, 1=sample no 1, 2=sample no 2, 3 = Sample no 3, 9 =Sample no 9. 28S = 28S ribosomal RNA (rRNA) bands, 18S = 18S ribosomal RNA.....120

**Figure 3.2** A photograph of total RNA isolated from human peripheral blood lymphocytes using RNA-STAT 60™ reagent and visualised by ethidium bromide staining on a 1.0 % agarose gel electrophoresis. Lane M = DNA Ladder, 4 = sample no 4, 5 = sample no 5, 6 = sample no 6, 7 =sample no 7. 28S = 28S ribosomal RNA (rRNA) bands, 18S = 18S ribosomal RNA.....121

**Figure 3.3** A photograph of total RNA isolated from human peripheral blood lymphocytes using RNA-STAT 60™ reagent and visualised by ethidium bromide staining on a 1.0 % agarose gel electrophoresis. Lane M = DNA Ladder, 8 = sample no 8. 28S = 28S ribosomal RNA (rRNA) bands, 18S = 18S ribosomal RNA.....122

**Figure 3.4** A photograph of total RNA isolated from human peripheral blood lymphocytes using RNA-STAT 60™ reagent and visualised by ethidium bromide

staining on a 1.0 % agarose gel electrophoresis. Lane M = DNA Ladder, 9 = sample no 9, 10 = sample no 10. 28S = 28S ribosomal RNA (rRNA) bands, 18S = 18S ribosomal RNA.....123

**Figure 3.5** A photograph of a gel showing the product from RT-PCR amplification of  $\alpha 4$  nAChR subunit mRNA from 1  $\mu$ g of human peripheral blood lymphocyte total RNA using the Access RT-PCR system. The expected product length was 387 bp. Lane M = DNA Ladder (100bp DNA Ladder), Lanes 1-10 = samples number 1-10, Lane +ve = positive control (human brain total RNA), Lane -ve = no RNA template.....126

**Figure 3.6** A photograph of a gel showing the product from RT-PCR amplification of  $\alpha 5$  nAChR subunit mRNA from 1  $\mu$ g of human peripheral blood lymphocyte total RNA using the Access RT-PCR system. The expected product length was 556 bp. Lane M = DNA Ladder (100bp DNA Ladder), Lanes 1-10 = samples number 1-10, Lane +ve = positive control (human brain total RNA), Lane -ve = no RNA template.....127

**Figure 3.7** A photograph of a gel showing the product from RT-PCR amplification of  $\alpha 7$  nAChR subunit mRNA from 1  $\mu$ g of human peripheral blood lymphocyte total RNA using the Access RT-PCR system. The expected product length was 451 bp. Lanes 1-10 = samples number 1-10, Lane +ve = positive control (human brain total RNA), Lane -ve = no RNA template, Lane M = DNA Ladder (100 bp DNA Ladder).....128

**Figure 3.8** A photograph of a gel showing the product from RT-PCR amplification of  $\beta 1$  nAChR subunit mRNA from 1  $\mu$ g of human peripheral blood lymphocyte total RNA using the Access RT-PCR system. The expected product length was 589 bp. Lane M = DNA Ladder (100 bp DNA Ladder), Lanes 1-10 = samples number 1-10, Lane +ve =

positive control (human brain total RNA), Lane -ve = no RNA template.....129

**Figure 3.9** A photograph of a gel showing the product from RT-PCR amplification of  $\beta 2$  nAChR subunit mRNA from 1  $\mu$ g of human peripheral blood lymphocyte total RNA using the Access RT-PCR system. The expected product length was 309 bp. Lanes 1-10 = samples number 1-10, Lane +ve = positive control (human brain total RNA), Lane -ve = no RNA template, Lane M = DNA Ladder (100 bp DNA Ladder).....130

**Figure 4.1** A photograph showing schematic of tank blotting method.....153

**Figure 4.2** Protein from rat brain and human peripheral blood lymphocytes samples (20  $\mu$ g/lane). The gel was stained with Coomassie Brilliant Blue. Lane M = Precision molecular weight marker (Bio-Rad), Lane R = rat brain protein, Lane No 1-6 = protein from human peripheral blood lymphocyte samples No 1-6. ....159

**Figure 4.3** Protein from rat brain and human peripheral blood lymphocytes samples (20  $\mu$ g/lane). The gel was stained with Coomassie Brilliant Blue. Lane M = Precision molecular weight marker (Bio-Rad), Lane R = rat brain protein, Lane No 7-12 = protein from human peripheral blood lymphocyte samples No 7-12.....160

**Figure 4.4** Western blot analysis of human lymphocytes was screened for the presence of nAChR  $\alpha 4$  subunit protein using a monoclonal antibody against  $\alpha 4$  nAChR protein subunit. The predicted molecular weight of the  $\alpha 4$  nAChR subunit is  $\approx 70$  kD. The protein products were visualised by ECL. Lane 1 = Perfect Protein HRP Western Makers (Novagen), Lane R = rat brain membrane protein, Lane No 1-6 = protein from human lymphocytes (samples No 1-6) ( $\leftarrow$  = predicted molecular weight).....161

**Figure 4.5** Western blot analysis of human lymphocytes was screened for the presence of nAChR  $\alpha 4$  using a monoclonal antibody against the  $\alpha 4$  nAChR subunit. The predicted molecular weight of the  $\alpha 4$  nAChR subunit is  $\approx 70$  kD. The protein products were visualised by ECL. Lane 1 = Perfect Protein HRP Western Markers (Novagen), Lane R = rat brain membrane protein, Lane No 7-12= protein from human lymphocytes (samples No 7-12) ( $\leftarrow$  = predicted molecular weight).....162

**Figure 4.6** Western blot analysis of human lymphocytes was screened for the presence of nAChR  $\alpha 5$  subunit protein using a monoclonal antibody against the  $\alpha 5$  nAChR subunit. The predicted molecular weight is  $\approx 53$  kD. In all samples, a band of the appropriate size was identified and the protein products were visualised by ELC. Lane 1= Perfect Protein HRP Western Markers (Novagen), Lane 2 = rat brain protein membrane, Lane 1-6 =samples from human lymphocytes (Samples No1 - 6) ( $\leftarrow$  = predicted molecular weight). .....163

**Figure 4.7** Western blot analysis of human lymphocytes was screened for the presence of nAChR  $\alpha 5$  subunit protein using a monoclonal antibody against the  $\alpha 5$  nAChR subunit. The predicted molecular weight is 53 kD. In all samples, a band of the appropriate size was identified and the protein products were visualised by ELC. Lane 1=Perfect Protein HRP Western Markers (Novagen), Lane 2=rat brain protein membrane, Lane No 7-12 = human lymphocytes (Samples No7 - 12) ( $\leftarrow$  = predicted molecular weight).....164

**Figure 4.8** Western blot analysis of human lymphocytes was screened for the presence of nAChR  $\alpha 7$  subunit protein using a monoclonal antibody against  $\alpha 7$  subunit. The predicted molecular weight is  $\approx 56.449$  kD. This antibody was specific to both human and rat  $\alpha 7$  subunit protein nAChR. In all samples, a band of the appropriate size was identified and the protein products were visualised by ELC. Lane 1= Perfect Protein

HRP Western Markers (Novagen), Lane 2=rat brain protein membrane, Lane No 1-6 = human lymphocytes (Samples No1- 6) (← = predicted molecular weight).....165

**Figure 4.9** Western blot analysis of human lymphocytes was screened for the presence of nAChR  $\alpha 7$  subunit protein using a monoclonal antibody against the  $\alpha 7$  nAChR subunit. The predicted molecular weight is  $\approx 56.449$  kD. In all samples, a band of the appropriate size was identified and the protein products were visualised by ELC. Lane 1 = Perfect Protein HRP Western Makers (Novagen), Lane 2 = rat brain protein membrane, Lane No 7-12 = human lymphocytes (Samples No7 - 12) (← = predicted molecular weight).....166

**Figure 4.10** Western blot analysis of human lymphocytes was screened for the presence of nAChR  $\beta 2$  subunit protein using a monoclonal antibody against the  $\beta 2$  nAChR subunit. The predicted molecular weight is  $\approx 57$  kD. In all samples, a band of the appropriate size was identified and the protein products were visualised by ELC. Lane 1 = Perfect Protein HRP Western Markers (Novagen), Lane 2 = rat brain protein membrane, Lane No 1-6 = human lymphocytes (Samples No1 - 6). .....167

**Figure 4.11** Western blot analysis of human lymphocytes was screened for the presence of nAChR  $\beta 2$  subunit protein using a monoclonal antibody against the  $\beta 2$  nAChR subunit. The predicted molecular weight is  $\approx 57$  kD. In all samples, a band of the appropriate size was identified and the protein products were visualised by ELC. Lane 1 = Perfect Protein HRP Western Markers (Novagen), Lane 2=rat brain protein membrane, Lane No 7-12 = human peripheral blood lymphocytes (Samples No7 - 12). (← = predicted molecular weight).....168

## LIST OF TABLES

<b>Table 1.1</b> The nAChR known 16 subunits are classified into subfamilies and groups on the basis of both gene structure and mature protein sequence.....	3
<b>Table 2.1</b> A table showing the IC <sub>50</sub> for the different ligands used in the competitive assay. All values were calculated from computer analysis from individual experiment and then the mean SEM of at least 4-5 experiments.....	89
<b>Table 2.2</b> A table showing the range of ligands used in the competitive assay that displaced [ <sup>3</sup> H]-(-)-nicotine from human peripheral blood lymphocytes. SPB = Specific binding.....	90
<b>Table 3.1</b> Forward and reverse primers for mRNA of nAChR subunits and the expected RT-PCR product size in base pairs (bp).....	114
<b>Table 3.2</b> The expression of mRNAs encoding nicotinic acetylcholine receptor subunits in human peripheral blood lymphocytes. The predicted products were observed by 1.5 % agarose gel electrophoresis.....	125
<b>Table 4.1</b> Reagents and volumes required for preparation of 10% SDS-PAGE resolving gel for 2 mini-gels.....	148
<b>Table 4.2</b> Reagents and volumes required for preparation of 5% SDS-PGAGE stacking gel for 2 mini-gels.....	150

## **ABBREVIATIONS**

$\alpha$ -BTX	alpha bungarotoxin
5HT <sub>3</sub>	5-hydroxytryptamine
ACh	acetylcholine
AChE	acetylcholine esterase
BE	bronchial epithelial cells
<i>B<sub>max</sub></i>	the density of receptor site in particular tissue
bp	base pair(s)
BSA	bovine serum albumin
CD	Crohn's disease
cDNA	complementary DNA
ChAT	choline acetyltransferase
Ci	curie
CNS	central nervous system
Da	Dalton(s)
DEPC	diethyl pyrocarbonate
DH $\beta$ E	dihydro-beta-erythroidine
DNA	deoxyribose nucleic acid
DNBS	dinitrobenzenesulphonic acid
DPM	disintegration per minute
DTT	dithiothreitol
EBI	European Bioinformatics Institute
ECL	enhance chemiluminescence
EDTA	ethylenediaminetetraacetic acid

FBS	foetal bovine serum
g	gram (s)
GABA	gamma-amino-butyric-acid
GI	gastro-intestinal
HBSS	Hanks' Balance Salt Solution
HEPES	N-2-Hydroxyethylpiperazine-N'-2-ethanesulfonic acid
HRP	horseradish peroxidase
IBD	inflammatory bowel disease
IC50	50% inhibitory concentration
IFN $\gamma$	interferon gamma
IgE	immunoglobulin E
IL-1	Interleukin-1
IL-2	interleukin 2
IP3	inositol-triphosphate
<i>K<sub>d</sub></i>	dissociation equilibrium constant
kDa	kilodalton
L	litre (s)
M	molar (s)
mA	milliamp
mAChR	muscarinic acetylcholine receptor
mCi	millicurie
mg	milligram (s)
ml	millilitre (s)
mM	millimolar (s)
mRNA	messenger ribonucleic acid

mV	milivolt (s)
nAChR	nicotinic acetylcholine receptor
NBTS	national blood transfusion services
NCBI	National Centre for Biotechnology Information
nM	nanomolar
PAGE	polyacrylamide gel electrophoresis
PBS	phosphate buffered saline
PBMC	peripheral blood mononuclear cells
PCR	polymerase chain reaction
PMN	polymorphonuclear
PVDF	electro blotting membrane
RNA	ribose nucleic acid
rpm	revolutions per minute
RT-PCR	reverse transcriptase polymerase chain reaction
SDS	sodium dodecyl sulphate
TAE	Tris-acetic acid-EDTA buffer
TEMED	N,N,N',N'-tetramethylenediamine
TNBS	trinitrobenzenesulphonic acid
TNF $\alpha$	tumour necrosis factor alpha
UC	ulcerative colitis
$\mu$ g	microgram (s)
$\mu$ l	microlitre (s)
$\mu$ M	micromolar (s)
UV	ultra violet
V	volts

## **LIST OF CHEMICALS AND REAGENTS**

<b><u>Chemical/Reagent</u></b>	<b><u>Supplier</u></b>
Access RT-PCR system	Promega
$\alpha$ -BTX	Sigma
Acetic acid	Sigma
Acetone	Fisher
Acrylamide	BDH
Agarose	National Diagnostics
Aprotinin	Sigma
Atropine	Sigma
Ammonium persulphate	Sigma
AMV reverse transcriptase	Promega
Anti- rat IgG HRP conjugate	Merck Biosciences
Anti- mose IgG HRP conjugate	Merck Biosciences
Bis-acrylamide	BDH
$\beta$ -Mercaptoethanol	Sigma
Bromophenol blue	Sigma
Buffy coat	National Blood Transfusion Services
Carbachol	Sigma
Chloroform	Sigma
Coomassie brilliant blue	Sigma
Cytisine	Sigma
D-glucose	Sigma

Diethyl pyrocarbonate	Sigma
Dithiothreitol	BDH
ECL kit	Amersham Pharmacia Biotech
EDTA (sodium salt)	BDH
Epibatidine	Torcris
Ethidium bromide	Sigma
Ficoll 400	Sigma
Foetal bovine serum	Life Technologies
General sterile plastics	Greiner Laborstechnik
Glycerol	Sigma
[ <sup>3</sup> H]-(-)-nicotine	NEN Life Sciences
HEPES	BDH
Hexamethonium	Sigma
Histopaque®-1077	Sigma
Hyperfilm	Amersham Pharmacia Biotech
IMS	Fisher
Isopropanol	Fisher
KH <sub>2</sub> PO <sub>4</sub>	BDH
Leupeptin	Sigma
L-glutamine	Life Technologies
Liquiscint scintillation fluid	National Diagnostics
MAB for α4, α5, β2 nAChR subunits	Covance Research products
MAB for α7 nAChR subunit	Research Diagnostics
NaCl	BDH
Na <sub>2</sub> HPO <sub>4</sub>	BDH

(-)-nicotine	Sigma
Nitrocellulose membrane	BDH
Nuclease free water	Promega
PBS tablets	Sigma
Penicillin	Life Technologies
Powdered milk (non-fat dried milk)	Marvell
Perfect protein™ HRP	Merck Biosciences
Prestained protein marker	Bio-rad
Primers	Invitrogen
RNA-STAT 60™	Biogenesis
RPMI-1640	Sigma
SDS	Fisher
Skatron 12 well micro tubes	Camo Ltd
Streptomycin	Life Technologies
Sucrose	BDH
TEMED	Sigma
Tissue culture flasks (75ml <sup>3</sup> )	Becton Dickinson
Tris base	BDH
Trypan Blue	Sigma
Tween-20	Sigma
Whatman GF/B filters	Sigma

